Sensorion SA
PAR:ALSEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sensorion SA
Net Issuance of Debt
Sensorion SA
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sensorion SA
PAR:ALSEN
|
Net Issuance of Debt
-€1.3m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Net Issuance of Debt
€61k
|
CAGR 3-Years
-88%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
-45%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Net Issuance of Debt
€65.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Net Issuance of Debt
-€6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Net Issuance of Debt
-$367k
|
CAGR 3-Years
55%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Net Issuance of Debt
€16.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Sensorion SA
Glance View
Sensorion SAS is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 34 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
See Also
What is Sensorion SA's Net Issuance of Debt?
Net Issuance of Debt
-1.3m
EUR
Based on the financial report for Dec 31, 2025, Sensorion SA's Net Issuance of Debt amounts to -1.3m EUR.
What is Sensorion SA's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
40%
Over the last year, the Net Issuance of Debt growth was 4%. The average annual Net Issuance of Debt growth rates for Sensorion SA have been -29% over the past three years , 40% over the past five years .
